A. C. Weyand and S. W. Pipe, New therapies for hemophilia, Blood, vol.133, issue.5, pp.389-398, 2019.

V. Muczynski, O. D. Christophe, C. V. Denis, and P. J. Lenting, Emerging Therapeutic Strategies in the Treatment of Hemophilia A, Semin Thromb Hemost, vol.43, issue.6, pp.581-590, 2017.

T. Kitazawa, T. Igawa, and Z. Sampei, A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model, Nat Med, vol.18, issue.10, pp.1570-1574, 2012.

T. Kitazawa, K. Esaki, and T. Tachibana, Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens, Thromb Haemost, vol.117, issue.7, pp.1348-1357, 2017.

P. J. Lenting, C. V. Denis, and O. D. Christophe, Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?, Blood, vol.130, issue.23, pp.2463-2468, 2017.

J. Oldenburg, J. N. Mahlangu, and B. Kim, Emicizumab Prophylaxis in Hemophilia A with Inhibitors, N Engl J Med, vol.377, issue.9, pp.809-818, 2017.

J. Mahlangu, J. Oldenburg, and I. Paz-priel, Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors, N Engl J Med, vol.379, issue.9, pp.811-822, 2018.

S. W. Pipe, M. Shima, and M. Lehle, Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study, Lancet Haematol, vol.6, issue.6, pp.295-305, 2019.

G. Young, R. Liesner, and T. Y. Chang, A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors, Blood, 2019.

N. C. Leksa, M. M. Aleman, A. G. Goodman, D. Rabinovich, R. Peters et al., Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence, J Thromb Haemost, vol.17, issue.7, pp.1044-1052, 2019.

M. M. Aleman, N. C. Leksa, R. Peters, and J. Salas, Assay challenges (and opportunities) with non-factor VIII therapies for Hemophilia A, Expert Rev Mol Diagn, vol.19, issue.1, pp.1-3, 2019.

R. Hartmann, T. Feenstra, L. Valentino, M. Dockal, and F. Scheiflinger, In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents, J Thromb Haemost, 2018.

Y. Dargaud, A. Lienhart, M. Janbain, L. Quellec, S. Enjolras et al., Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab, Haematologica, vol.103, issue.4, pp.181-183, 2018.

L. Bi, A. M. Lawler, S. E. Antonarakis, K. A. High, J. D. Gearhart et al., Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A, Nat Genet, vol.10, issue.1, pp.119-121, 1995.

H. C. Hemker, P. Giesen, and R. Aldieri, The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiology of haemostasis and thrombosis, vol.32, pp.249-253, 2002.

J. I. Adamkewicz, D. C. Chen, and I. Paz-priel, Effects and Interferences of Emicizumab

, Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays, Thromb Haemost, vol.119, issue.7, pp.1084-1093, 2019.

T. Gui, H. F. Lin, and D. Y. Jin, Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo, Blood, vol.100, issue.1, pp.153-158, 2002.

V. Muczynski, S. Verhenne, and C. Casari, A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A, Thromb Haemost, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02570572

M. Andrew, B. Paes, and R. Milner, Development of the human coagulation system in the full-term infant, Blood, vol.70, issue.1, pp.165-172, 1987.

M. Andrew, B. Paes, and R. Milner, Development of the human coagulation system in the healthy premature infant, Blood, vol.72, issue.5, pp.1651-1657, 1988.

B. Cooley, W. Funkhouser, and D. Monroe, Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice, Blood, vol.128, issue.2, pp.286-292, 2016.

S. Verhenne, C. Loubière, C. V. Denis, P. J. Lenting, and O. D. Christophe, An inducible mouse model of factor X deficiency to test novel factor X therapeutics. Research and Practice in Thrombosis and Haemostasis, vol.3, 2019.

W. Li, J. Hu, and N. Leksa, A novel humanized hemophilia-a mouse model to facilitate preclinical in vivo studies of human specific FVIIIa-mimetic bispecific antibodies, Blood, vol.132, 2018.